ArticleHereditas2025
Unveiling the mechanisms of yanhusuo's therapeutic effects in neuropathic pain through network pharmacology, single-cell RNA sequencing, and molecular docking.
Article in Hereditas, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Anticancer Effects ofIranian journal of pharmaceutical research : IJPRArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundCurrent therapeutic strategies for neuropathic pain (NP) encompass pharmacological agents, physical modalities, psychological support, and interventional procedures, which aim to mitigate inflammation, enhance vascular perfusion in afflicted regions, and modulate immune responses. However, the heterogeneity of NP pathogenesis and individual variability often lead to inconsistent treatment outcomes.
methodsAn integrative network pharmacology framework was employed to elucidate the mechanistic basis of Yanhusuo in NP management. NP patients were categorized via unsupervised clustering, followed by single-cell sequencing and cell-cell communication analysis to identify immune cell interactions. Active compounds and targets of Yanhusuo were identified using the Traditional Chinese Medicine Systems Pharmacology (TCMSP) and SwissTargetPrediction databases. Network pharmacology tools, including Cytoscape, facilitated the construction of protein-protein interaction (PPI), compound-target-disease, and compound-target-pathway networks. Topological analyses identified core targets and pathways, while the Database for Annotation, Visualization and Integrated Discovery (DAVID) bioinformatics platform was used for functional enrichment analysis. Finally, molecular docking analysis was conducted to evaluate ligand-receptor binding affinities.
resultsNine bioactive compounds and 53 NP-associated targets were identified in Yanhusuo. PPI analysis suggests that ACTB, PPP1CA, ERK1, and PTEN may be the hub nodes with maximal centrality. KEGG pathway enrichment highlighted the focal adhesion pathway as pivotal in Yanhusuo's anti-NP activity. Molecular docking suggests that there may be strong binding interactions between key compounds and hub targets (e.g. binding energy<-6.5 kcal/mol).
conclusionsThis work systematically maps Yanhusuo's multi-target, multi-pathway therapeutic landscape in NP, offering a strategic foundation for mechanistic research and drug discovery. The identified bioactive candidates represent promising candidates for NP therapeutics.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.